- TG Therapeutics (TGTX, Financial) presented new data on BRIUMVI for relapsing multiple sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting.
- The presentation included findings on immunoglobulin levels, infusion tolerability, and safety from key studies.
- Updated data and materials will be available on TG Therapeutics' website throughout the year.
TG Therapeutics, Inc. (TGTX) showcased three pivotal studies on BRIUMVI (ublituximab-xiiy) aimed at advancing the treatment landscape for relapsing forms of multiple sclerosis (RMS). This data was presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.
Key findings included a study led by Dr. Bruce Cree from the Weill Institute for Neurosciences, which detailed long-term observations on serum immunoglobulin levels and infection risks associated with ublituximab treatment. Dr. Edward Fox from TG Therapeutics presented real-world infusion tolerability data from the ENAMOR survey, while Dr. John Foley from Rocky Mountain Multiple Sclerosis shared safety updates from the ENHANCE study, which focused on the efficacy of 30-minute infusions.
The company remains committed to providing ongoing updates and insights related to BRIUMVI, making all presentation materials available on their website at www.tgtherapeutics.com/publications.cfm.
BRIUMVI, already approved by the FDA for RMS, is a novel monoclonal antibody targeting CD20-expressing B-cells, demonstrating advancements in autoimmune disorder management through its unique glycoengineering design for efficient B-cell depletion. TG Therapeutics continues to leverage these findings to maintain momentum in its biopharmaceutical endeavors.
